MARKET PULSE-Chelsea, YRC, Pharmerica, Intercept, Mannkind, Perceptron
(For more market insights, including options activity, click on ; for the Day Ahead newsletter link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stocks were little changed on Friday after the December payroll report came in much weaker than expected, raising new questions about both the strength of the economy and the aggressiveness of Federal Reserve stimulus. The Dow Jones industrial average was down 0.07 percent at 16,432.71, the S&P 500 was up 0.21 percent at 1,841.95 and the Nasdaq Composite was down 0.02 percent at 4155.18.
** CHELSEA THERAPEUTICS INTERNATIONAL LTD, $2.49, -29.46 pct
U.S. Food and Drug Administration reviewers said a treatment developed by Chelsea for a rare type of low blood pressure lack evidence that the drug's benefit is durable over a longer period of time, according to documents on the FDA's website.
** RETROPHIN INC, $11.43, +34.47 pct
The pharmaceutical company said it expects gross proceeds of $40 million from a share offering and use it to develop its nasal spray to aid milk ejection for breastfeeding mothers. It will also use the fund to start trials for some of its experimental drugs.
** FRANCESCA'S HOLDINGS CORP, $22.38, +23.78 pct
The women's clothing retailer raised the low end of its sales and earnings forecasts for the fourth quarter ending Feb. 1 based on strong sales during the holiday period. Continued...